NASDAQ:ACTU Actuate Therapeutics (ACTU) Stock Price, News & Analysis $2.38 -0.04 (-1.65%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.40 +0.02 (+1.05%) As of 05/22/2026 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Actuate Therapeutics Stock (NASDAQ:ACTU) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Actuate Therapeutics alerts:Sign Up Key Stats Today's Range$2.36▼$2.7950-Day Range$1.72▼$3.3452-Week Range$1.58▼$11.99Volume57,535 shsAverage Volume135,963 shsMarket Capitalization$56.95 millionP/E RatioN/ADividend YieldN/APrice Target$17.50Consensus RatingHold Company Overview Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers. The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors. By inhibiting CDK9, atuveciclib is designed to disrupt transcription-dependent survival pathways in malignant cells. In addition to its CDK9 program, Actuate is advancing preclinical research on a tumor-homing peptide–drug conjugate that aims to selectively deliver cytotoxic payloads to integrin-expressing tumor cells, thereby enhancing therapeutic index and minimizing off-target effects. Since its founding in 2018, Actuate has built its research and development operations in the San Francisco Bay Area, leveraging collaborations with leading academic institutions and contract research organizations. The company’s clinical trials are currently conducted at premier oncology centers across the United States, with plans to expand its geographic footprint into Europe and Asia as its pipeline advances through development milestones. Actuate’s leadership team comprises industry veterans with extensive experience in oncology research, translational science and biopharmaceutical commercialization. By combining deep scientific expertise with a streamlined development strategy, the company aims to rapidly advance its targeted therapies toward clinical proof of concept and ultimately to regulatory approval.AI Generated. May Contain Errors. Read More Actuate Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreACTU MarketRank™: Actuate Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 646th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingActuate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialActuate Therapeutics has a consensus price target of $17.50, representing about 635.3% upside from its current price of $2.38.Amount of Analyst CoverageActuate Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Actuate Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Actuate Therapeutics are expected to grow in the coming year, from ($0.86) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Actuate Therapeutics is -2.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Actuate Therapeutics is -2.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioActuate Therapeutics has a P/B Ratio of 14.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.51% of the float of Actuate Therapeutics has been sold short.Short Interest Ratio / Days to CoverActuate Therapeutics has a short interest ratio ("days to cover") of 3.84, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Actuate Therapeutics has recently increased by 3.58%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldActuate Therapeutics does not currently pay a dividend.Dividend GrowthActuate Therapeutics does not have a long track record of dividend growth. News and Social Media1.1 / 5News Sentiment-0.26 News SentimentActuate Therapeutics has a news sentiment score of -0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Actuate Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for ACTU on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Actuate Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Actuate Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders57.98% of the stock of Actuate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsActuate Therapeutics has minimal institutional ownership at this time.Read more about Actuate Therapeutics' insider trading history. Receive ACTU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actuate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACTU Stock News HeadlinesActuate Therapeutics (NASDAQ:ACTU) Lowered to Sell Rating by Wall Street ZenMay 23 at 1:28 AM | americanbankingnews.comActuate Therapeutics Adds Oncology Expert to Board LeadershipMay 22 at 5:13 PM | theglobeandmail.comSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billion - you'd be buying at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's path, still priced like Wall Street hasn't noticed. It powers the infrastructure Musk's operation can't run without. Dylan Jovine is naming the ticker free - before the June S-1 closes the window.May 24 at 1:00 AM | Behind the Markets (Ad)HC Wainwright Has Pessimistic View of ACTU FY2030 EarningsMay 20, 2026 | americanbankingnews.comActuate Therapeutics Insider Trading Activity | NASDAQ:ACTU | BenzingaMay 20, 2026 | benzinga.comActuate Therapeutics (NASDAQ:ACTU) Given Buy Rating at HC WainwrightMay 19, 2026 | americanbankingnews.comActuate Therapeutics (ACTU) price target decreased by 15.66% to 17.85May 15, 2026 | msn.comActuate Wins FDA Clearance for Oral Elraglusib TrialMay 11, 2026 | tipranks.comSee More Headlines ACTU Stock Analysis - Frequently Asked Questions How have ACTU shares performed this year? Actuate Therapeutics' stock was trading at $6.12 at the beginning of 2026. Since then, ACTU stock has decreased by 61.1% and is now trading at $2.38. How were Actuate Therapeutics' earnings last quarter? Actuate Therapeutics, Inc. (NASDAQ:ACTU) posted its quarterly earnings data on Thursday, May, 14th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.01. When did Actuate Therapeutics IPO? Actuate Therapeutics (ACTU) raised $27 million in an IPO on Tuesday, August 13th 2024. The company issued 3,000,000 shares at $8.00-$10.00 per share. Titan Partners acted as the underwriter for the IPO and Newbridge Securities Corp. was co-manager. Who are Actuate Therapeutics' major shareholders? Top institutional shareholders of Actuate Therapeutics include ABS Direct Equity Fund LLC (0.21%) and Royal Bank of Canada (0.09%). Insiders that own company stock include Todd S Thomson, Leslie W Kreis, Aaron GL Fletcher and Equity Cof Lp Bios. View institutional ownership trends. How do I buy shares of Actuate Therapeutics? Shares of ACTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Actuate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Actuate Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN) and Company Calendar Last Earnings5/14/2026Today5/24/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 3 weeks, ACTU's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACTU Previous SymbolNASDAQ:ACTU CIK1652935 WebN/A Phone(847) 986-4190FaxN/AEmployees10Year Founded2015Price Target and Rating Average Price Target for Actuate Therapeutics$17.50 High Price Target$20.00 Low Price Target$15.00 Potential Upside/Downside+635.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.23 million Net MarginsN/A Pretax MarginN/A Return on Equity-430.93% Return on Assets-180.86% Debt Debt-to-Equity RatioN/A Current Ratio1.80 Quick Ratio1.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.16 per share Price / Book14.88Miscellaneous Outstanding Shares23,930,000Free Float10,054,000Market Cap$56.95 million OptionableN/A Beta0.92 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ACTU) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
